Pakistan Pharmaceutical Manufacturers’ Association has urged Prime Minister Nawaz Sharif to sign summaries sent by the Drug Pricing Committee in 2016. They do so in order to ease the sufferings and pains of patients.
According to MPA about 100 important medicines have gone short in the domestic market. They have gone short because of delay in approval of recommendations sent by the Drug Pricing Committee last year.
The PPMA chairman insisted that such matters should have been dealt with by Drug Regulatory Authority of Pakistan. They should not send to a ministry and later to the Prime Minister’s Office.
Waheed said that the production and availability of a number of life-saving drugs, new and orphan molecules in Pakistan market had been extremely affected due to indecision on the part of the prime minister.
For example, Hepatitis C patients have yet to get access to the medicine Daclatasvir. This tablet contains a miraculous cure for people suffering from this fatal disease that was earlier considered incurable.
Waheed pointed out that panel inspection had been made mandatory for the pharma industry. Pharma industry uses to apply to Drap’s registration board for introducing new medicines in Pakistan market. He was of the view that systems like panel inspection would only delay manufacturing and introduction of new medicines.
Most K-P health centers run short of sufficient medicine stocks.
He claimed that billions of rupees are not being used in the Central Research Fund. The industry should have access to this fund for utilizing the unused capital for its own growth, especially in relation to export requirements.
Waheed said the government should stop the money demanded in the name of research fund which had been of no use so far.